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Fulminant liver failure associated with




Hepatic dysfunction during hyperthyroidism frequently occurs with mild abnormalities in liver function tests that
are self-limited, improving after treatment of thyroid disease. With the exception of congestive heart failure or
secondary hepatic disease, significant hepatic compromise during thyrotoxicosis is rare and often of unexplained
origin. This report identifies a novel case of severe hepatic compromise in the setting of thyrotoxicosis that was not
initially identified due to a falsely elevated TSH. A 43-year-old African-American man presented to the intensive care
unit with severe jaundice, weight loss, thyroid bruit and altered mental status. Initial diagnosis of hyperthyroidism
was delayed due to a non-suppressed TSH of 0.20 μU/mL. Laboratory studies identified dramatic hepatic synthetic
dysfunction and elevated transaminases with a total bilirubin of 47.4 mg/dL, AST 259 U/L, and ALT 142 U/L. No
toxins, structural or viral causes of liver disease were identified and the patient was prepared for potential liver
biopsy. Heterophile antibodies were identified and removed by precipitation, demonstrating an undetectable TSH
and free thyroxine 9.0 ng/dL consistent with hyperthyroidism. Subsequent treatment with thionamides, corticosteroids,
and potassium iodide improved both thyroid and liver function and avoided unnecessary invasive testing. Heterophile
antibodies remain as important interfering factors in TSH immunoassays, and thus, this case demonstrates the
importance of matching the clinical picture with available laboratory data. In the absence of a known cause of hepatic
dysfunction, hyperthyroidism should be considered as a potential etiology of acute liver failure of unknown origin.
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Background
Mild hepatic dysfunction is common during hyperthyroid-
ism and is most frequently associated with abnormalities
in liver function tests [1, 2]. While mild elevations in
serum alkaline phosphatase values are most frequently as-
sociated with hyperthyroidism, severe hepatic dysfunction
complicated by jaundice has been rarely found in cases of
severe thyrotoxicosis [3–7]. Most often, alterations in
serum liver tests are self-limited and resolve following
treatment and improvement of hyperthyroidism [1, 2].
Significant hepatic dysfunction and evidence of liver
failure is an infrequent consequence of hyperthyroidism,
most frequently associated with congestive heart failure
or underlying secondary hepatic dysfunction [7]. This re-
port identifies a novel case of severe hepatic compromise
in the setting of thyrotoxicosis, which was potentially ex-
acerbated due to a delayed diagnosis of thyrotoxicosis
secondary to heterophilic antibody interference with the
thyrotropin (TSH) assay.
Case presentation
A 43-year-old homeless African-American man pre-
sented to the intensive care unit with severe jaundice
and altered mental status. The patient had an uninten-
tional 100 lb. weight loss over the previous 6 months,
along with rapid heart rate, extreme fatigue, and fre-
quent diarrhea. Two weeks prior to admission, the pa-
tient was evaluated for nausea, vomiting, jaundice, and
dehydration and was discharged home to arrange out-
patient follow-up of an unspecified hepatic and thyroid
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defect. He had no previous history of liver disease, exposure
to jaundiced people or hepatitis, exposure to hepatotoxins
(such as acetaminophen), alcohol ingestion, or drug abuse
and was not taking any medications. Physical examination
revealed an ill-appearing, cachectic man with temporal
wasting who was unresponsive to external stimuli. His
pulse was 150 beats/min and irregular; blood pressure 140/
70 mmHg, temperature 36.7 °C, and weight 146 lb. Sclerae
were icteric, but without proptosis or exophthalmos. His
thyroid gland was diffusely enlarged (40 g by palpation)
with a palpable thyroid thrill and audible thyroid bruit.
There were no palpable thyroid nodules. Cardiovascular
examination revealed an irregular rate and rhythm, no
jugular venous distension, and no murmurs. The patient
had a tender right upper quadrant on palpation of his abdo-
men, with hepatomegaly palpable 4–5 cm below the costal
margin and no ascites. Neurologic examination revealed a
resting tremor with hyperreflexia.
Laboratory data was remarkable for an elevated total
bilirubin of 47.4 mg/dL (normal range: 0.2–1.2 with dir-
ect bilirubin of 44.6 mg/dL, delta bilirubin of 18.5 mg/
dL, conjugated bilirubin of 26.1 mg/dL, unconjugated
bilirubin of 2.8 mg/dL); aspartate aminotransferase of
259 U/L (AST; normal range: 8–60); alanine aminotrans-
ferase 142 U/L (ALT: normal range 14–78), alkaline
phosphatase 307 U/L (normal range: 38–126 U/L); albu-
min 3.3 mg/dL (normal range 3.5–5.0); and prothrombin
time (PT) >90 s. Complete blood count, platelets, and
reticulocyte count were within reference ranges. Blood
and urine toxicology (including alcohol), hepatitis A/B/C
serologies, antinuclear antibodies, anti-mitochondrial
antibodies, anti-gliadin antibodies, and HIV serology re-
sults were negative. Serum haptoglobin, ceruloplasmin,
CEA, CA 19–9, AFP measurements were within normal
limits. Electrocardiogram revealed atrial fibrillation and
echocardiogram demonstrated tachycardia, preserved
cardiac function with an ejection fraction of 70 %, and
no evidence of congestive heart failure. Abdominal CT
imaging revealed hepatomegaly without evidence of focal
hepatic mass, inflammation, or vascular obstruction.
The lack of a specific diagnostic cause for fulminant liver
failure led to planning for hepatic biopsy to determine a
potential pathologic liver defect.
Thyroid function studies revealed a thyroid-stimulating
hormone of 0.20 μU/mL (TSH; normal range: 0.4–4.0);
total thyroxine 15.2 μg/dL (total T4; normal range 4.5–
12.5); free thyroxine 9.0 ng/dL (free T4; normal range
0.89–1.80); T3 uptake 1.98 (normal range 0.9–1.3 TBI);
and total triiodothyronine 3.2 ng/mL (total T3; normal
range 0.6–1.71). The patient’s history of homelessness as
well as reported contact with rodents (and thus rodent an-
tigens) raised the suspicion that measured TSH values
were falsely elevated due to heterophile antibody interfer-
ence with the TSH assay. Heterophile antibodies consist of
natural antibodies that are weak and polyspecific antibodies
capable of interference with immunoassays, such as TSH
[8]. Following removal of human anti-mouse antibodies
(HAMA) by precipitation, subsequent measurement of
TSH concentration was <0.01 mU/L. Furthermore, a screen
for HAMA was positive.
Based on previously published diagnostic guidelines
[9], a clinical and laboratory diagnosis of thyroid storm
due to Graves’ disease was made and treatment with
propylthiouracil (PTU; 400 mg every 6 h), potassium
iodide, corticosteroids, and beta blockers was initiated
by the end of the second day of hospitalization. After
24 h of treatment, free T4 and total T3 levels began to
decline, while total T4 levels rose, potentially related to
the acute inhibitory activity of PTU on type 1 deiodinase
[10, 11]. Within 2–3 days of therapy, liver function studies
began to improve, along with improvement of T4 levels.
By day 5 of therapy, mental status and functioning im-
proved. Corticosteroids were discontinued within 10 days
of treatment. Scleral icterus and jaundice resolved by day
15 of treatment. From days 10–25, thyroxine levels
dropped below normal control concentrations, and thio-
namides and iodide were briefly discontinued. Of note,
thionamide therapy with PTU was initiated at the outset
of treatment, but briefly substituted with methimazole due
to concern over hepatic toxicity. These concerns were ul-
timately unfounded, as a lower dosage of PTU (200 mg
every 8 h) was reintroduced by one month after treatment
initiation and was maintained with dramatic improvement
of total bilirubin, AST, and ALT levels (detailed in Fig. 1).
Hepatic synthetic activity also dramatically improved as
prothrombin time and albumin concentrations returned
to reference ranges within 2–3 weeks. Alkaline phosphat-
ase concentrations improved by one month of treatment,
but not completely to normal ranges, prompting an evalu-
ation of bone and liver isoenzymes, which were both ele-
vated; bone-specific alkaline phosphatase of 88 IU/L
(normal range: 0–55) and liver-specific alkaline phosphat-
ase of 278 IU/L (normal range: 16–70) by 2 weeks of ther-
apy. By 4 weeks after treatment, the patient was moved to
an inpatient rehabilitation facility, where he subsequently
gained weight and improved his functional conditioning
while continuing PTU therapy. Prior to discharge from
the hospital, an I-123 uptake and nuclear scan was per-
formed revealing diffuse 74 % uptake at 2 h and 43 % up-
take at 24 h. He was subsequently treated with 18.7 mCi
of I-131 for ablative therapy.
Given his severe liver failure during thyrotoxicosis,
previous studies have suggested that an underlying de-
fect in bilirubin metabolism could be aggravated by
thyrotoxicosis [12, 13]. In order to test for the presence
of genetic mutations affecting bilirubin metabolism, gen-
omic DNA was extracted from peripheral blood using a
commercially available kit (Genetra systems, Inc.) and
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followed by automated DNA sequencing [14] at a refer-
ence laboratory at the Children’s Hospital of Philadelphia.
The patient was found to be heterozygous for Gilbert’s
syndrome, an autosomal recessive disorder, which is char-
acterized by mild, unconjugated hyperbilirubinemia in the
absence of liver disease or hemolysis. Gilbert’s syndrome is
due to the presence of genetic defects in the promoter re-
gion of the UGT1A1 gene, which encodes the UDP-
glucuronosyltransferase enzyme and is a key component
for efficient biliary excretion of bilirubin [15]. Patients
with Gilbert’s syndrome possess an additional TA repeat
in the TATAA element of the 5′ promoter of the gene
((TA)7TAA rather than the normal (TA)6TAA), but pa-
tients with heterozygous mutations for Gilbert’s syndrome
are often asymptomatic and do not exhibit hyperbiliru-
binemia. Furthermore, the patient did not have sup-
pression or absence of albumin-bound delta bilirubin, a
phenomenon reported during hyperbilirubinemia sec-
ondary to hemolysis or Gilbert’s syndrome [16].
Conclusions
This patient experienced severe hepatic dysfunction in
the setting of Graves’ disease and thyroid storm. Unique
to this case was the presence of heterophile antibodies
to the TSH assay, which led to a delayed diagnosis and
treatment of hyperthyroidism, as a thyroid-derived liver
defect was not initially considered. Changes in thyroid
laboratory tests secondary to critical illness [17, 18],
Fig. 1 Both liver and thyroid function studies improve following treatment for hyperthyroidism. Total T4 (reference range 4.5–12.5 μg/mL), free T4
(reference range 0.89–1.80 ng/dL), total bilirubin (reference range 0.2–1.2 mg/dL), alkaline phosphatase (reference range 38–126 U/L), total T3
(reference range 0.6–1.71 ng/dL), T3 uptake (reference range 0.90–1.30 TBI) AST (reference range 8–60 U/L), ALT (reference range 14–78 U/L)
levels measured over hospital course during therapy with propylthiouracil (PTU; orange), methimazole (MMI; blue), corticosteroids (dexamethasone;
green), and potassium iodide (SSKI; purple). PTU 400 mg q6 h, dexamethasone, and SSKI 4 drops q6 h were started on the end of day 2 of
hospitalization. Dexamethasone was discontinued and PTU was reduced to 200 mg q8 h on day 9. SSKI was reduced to 2 drops q8 h on day
12. PTU was discontinued and MMI 40 mg daily was initiated on day 13. MMI and SSKI were discontinued on days 16 and 18, respectively.
PTU was then restarted at 200 mg q8 h on day 25 and maintained at 150 mg q8 h after day 37 of hospitalization
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otherwise known as sick euthyroid syndrome, were con-
sidered in the patient’s differential diagnosis but appeared
less likely despite the overt pathognomonic signs of hyper-
thyroidism and dramatically elevated total and free T4
values. Furthermore, TBG excess (with reduced T3 resin
uptake) secondary to acute hepatitis was considered as a
potential etiology for the patient’s thyroid laboratory ab-
normalities [19, 20], but this possibility seemed less likely
as the patient displayed an elevation in his T3 uptake. Co-
existing autoimmune liver diseases (autoimmune hepatitis
or primary biliary cirrhosis) were also considered as po-
tential causes of hepatic dysfunction, but these diagnoses
seemed less likely due to the absence of ANA or anti-
mitochondrial antibodies as well as the acuity of his pres-
entation and his laboratory results [21]. Moreover, the
subsequent treatment of thyrotoxicosis not only improved
thyroid status, but also resolved liver dysfunction, which
would not be anticipated with sick euthyroid syndrome,
TBG excess, or autoimmune liver disease.
TSH measurements are a critical component in the
diagnosis of thyroid disorders. While 3rd generation TSH
immunoassays offer substantial sensitivity in the deter-
mination of thyroid function, these immunoassays can
still suffer from interference from heterophile antibodies
[22]. The generalized incidence of heterophile antibodies
is variable but has been reported to be as high as 10.4–
11.7 % of all patients, with an increased risk for develop-
ment in patients who have received animal-derived
pharmaceutical immunoglobulin therapies, blood trans-
fusions, vaccinations, as well as naturally encountered
antigens from pets or due to animal husbandry [23, 24].
Given this patient’s exposure to rodent antigens while
homeless, it is possible that the formation of HAMA led
to the falsely elevated TSH that delayed his diagnosis.
The aberrant elevation of this patient’s TSH concentra-
tions serves as a reminder of the importance of ensuring
the clinical picture matches available laboratory data to
prevent unnecessary testing, procedures, or morbidity.
Liver dysfunction is a common occurrence in hyper-
thyroidism, but its etiology is not well known. Previous
histopathologic analyses note diverse changes in the
livers of patients with hyperthyroidism-induced hepatic
dysfunction, ranging from intracellular cholestasis, in-
flammation with hepatocellular damage, to overt cirrho-
sis [2, 25]. Interestingly, pre-clinical models demonstrate
that hyperthyroidism can impair UDP glucuronosyl-
transferase activity and to lead to elevated bilirubin
levels [13]. Furthermore, a previous report has observed
cases of jaundice with thyrotoxicosis in patients with la-
tent defects in UDP-glucuronosyltransferase activity due
to Gilbert’s disease [12]. While we could not measure
UDP- glucuronosyltransferase activity in this patient, it
should be noted that patients with heterozygous muta-
tions for Gilbert’s disease do not normally exhibit hepatic
dysfunction, and this patient did not appear to have any
other known secondary cause (such as CHF or underlying
liver disease) to precipitate hepatic compromise. While
routine genetic screening may not always be indicated for
patients with hyperthyroidism and concomitant severe
liver disease, future studies will be invaluable to determine
the molecular mechanisms of severe hepatic compromise
in patients with thyroid storm.
Elevated alkaline phosphatase levels are a common
consequence following the resolution of hyperthyroid-
ism, likely due to elevations in bone-specific alkaline
phosphatase [3]. Serum alkaline phosphatase levels often
take several months to improve following resolution of
hyperthyroidism, as enhanced bone turnover likely per-
sists [1, 26]. These observations are consistent with this
patient’s presentation, as both bone and liver specific al-
kaline phosphatase levels continued to be elevated
within weeks of therapy.
In summary, this is a novel case of severe hepatic dys-
function in the setting of thyrotoxicosis compounded by
the presence of heterophile antibodies. Importantly, early
identification and treatment of Graves’ disease based upon
his clinical signs and symptoms, rather than laboratory
studies alone, may have prevented severe morbidity due to
delayed treatment. Additionally, in patients with thyrotoxi-
cosis and subsequent hyperbilirubinemia, treatment of
thyroid dysfunction with thionamides is safe and effective
resulting in improved liver function. These findings may
be of benefit to endocrinologists in understanding liver
disease in thyrotoxic patients or to gastroenterologists in
the identification of the etiology of acute liver failure of
unknown origin.
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